News and Announcements
FileInvite: $1 Million Raised and 100,000 Users
- Published December 18, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
FileInvite goes from strengh to strengh as the expanded team push out new features and are
set to massively expand growth in 2019.
With funding to capitalise on early growth and drive things forward, FileInvite closed pre-series equity funding round of over $1 Million in March 2018. New investors include high profile names in the New Zealand & Australian investment space including Flying Kiwi Angels, New Zealand Venture Investment Fund (NZVIF), as well as Ice Angels, Enterprise Angels and a handful of private individuals from around Australia.
With the investment comes a new addition to the board, Garth Hinton of FKA who brings a wealth of experience to the team, as well as connections and knowledge in the corporate banking space.
Other notable achievements in 2018:
- Over 100,000 end user milestone surpassed
- Tripled team size and moved to new premises
- More than doubled recurring revenue within the year
- First NZ main bank customer, largest New Zealand Owned Bank
- First NZ Government entity as a customer
- High profile customers including, Mortgage Broker of The Year
- Expanded North American customer base and opened new verticals
- 5 star independent customer reviews increased by 250%
About FileInvite
Fileinvite.com is a SaaS platform for document collection. Solving the problem of requesting and collecting client documentation, FileInvite has rapidly gained traction with users and revenue across Australia, USA, Canada and New Zealand.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
